EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Dual Antiplatelet Therapy in Patients With Metabolic Syndrome After Mild Ischemic Stroke or Transient Ischemic Attack

Zhang Xia iD, Ying Gao, Weiqi Chen iD, S Claiborne Johnston iD, Pierre Amarenco iD, Philip M Bath iD, Xuan Wang iD, Hongyi Yan iD, Tingting Wang iD, Yingying Yang iD, Yanli Zhang iD, Mengxing Wang und 5 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.041449 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Zhang Xia und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Beijing Tiantan Hospital, Capital Medical University Beijing China. Hauptthemen laut MEDLINE: Ischemic Attack, Transient, Aspirin, Clopidogrel, Metabolic Syndrome. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic syndrome (MetS) attenuates antiplatelet agent effects. This study investigated the efficacy and safety of clopidogrel–aspirin therapy for secondary stroke prevention in patients with MetS.

Methods

Data were obtained from the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High‐Risk Intracranial or Extracranial Atherosclerosis) trial. Patients with mild ischemic stroke or high‐risk transient ischemic attack were randomized to treatment with clopidogrel–aspirin or aspirin alone within 72 hours after symptom onset. MetS was defined according to the Adult Treatment Panel‐III. The primary efficacy outcome was new stroke, and the primary safety outcome was moderate ‐ to ‐ severe bleeding within 90‐day follow‐up. Differences between groups were estimated with Cox proportional hazards models, with hazard ratio (HR) and 95% CI presented.

Results

This study included 4715 patients, with a mean age of 63.7±9.6 years, 35.8% of women, and 75.8% of patients having MetS. After adjustment for potential confounders, patients with MetS were at higher risk of recurrent stroke (HR, 1.39 [95% CI, 1.06–1.82]; P =0.02) but not moderate ‐ to ‐ severe bleeding events (HR, 1.02 [95% CI, 0.47–2.21]; P =0.97) as compared with patients without MetS. However, MetS state did not impact the efficacy of clopidogrel–aspirin therapy for recurrent stroke ( P for interaction=0.44) and the safety for moderate‐to‐severe bleeding events ( P for interaction=0.54).

Conclusions

MetS was associated with higher risk of recurrent stroke at 90 days. There was no difference in the effect of clopidogrel–aspirin therapy on reducing new stroke and increasing moderate‐to‐severe bleeding events between patients with and without MetS. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03635749.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic Attack, TransientAspirinClopidogrelMetabolic SyndromePlatelet Aggregation InhibitorsIschemic StrokeDual Anti-Platelet TherapySecondary PreventionHumansFemaleMaleMiddle AgedAgedTreatment OutcomeHemorrhageRecurrenceRisk Factors

Stichwörter der Autor:innen

dual antiplatelet therapyischemic strokemetabolic syndromesecondary prevention

Substanzen

AspirinClopidogrelPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Neurology Beijing Tiantan Hospital, Capital Medical University Beijing China.
  • China National Clinical Research Center for Neurological Diseases Beijing China.
  • Department of Neurology University of California San Francisco CA USA.
  • Department of Neurology and Stroke Center Assistance Publique-Hôpitaux de Paris (APHP), Bichat Hospital, INSERM LVTS-U1148, University of Paris France.
  • Population Health Research Institute, McMaster University Hamilton Ontario Canada.
  • Stroke Trials Unit, Mental Health & Clinical Neuroscience University of Nottingham United Kingdom.

ORCID-Profile: Zhang Xia, Weiqi Chen, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Xuan Wang, Hongyi Yan, Tingting Wang, Yingying Yang, Yanli Zhang, Jing Jing, Chunjuan Wang, Yongjun Wang, Yilong Wang, Yuesong Pan

Zitieren

APA

Xia, Z., Gao, Y., Chen, W., Johnston, S. C., Amarenco, P., Bath, P. M., Wang, X., Yan, H., Wang, T., Yang, Y., Zhang, Y., Wang, M., Jing, J., Wang, C., Wang, Y., Wang, Y., & Pan, Y. (2025). Dual Antiplatelet Therapy in Patients With Metabolic Syndrome After Mild Ischemic Stroke or Transient Ischemic Attack. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041449

Vancouver

Xia Z, Gao Y, Chen W, Johnston SC, Amarenco P, Bath PM, et al. Dual Antiplatelet Therapy in Patients With Metabolic Syndrome After Mild Ischemic Stroke or Transient Ischemic Attack. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041449

BibTeX
@article{Xia2025,
  author = {Xia, Zhang and Gao, Ying and Chen, Weiqi and Johnston, S Claiborne and Amarenco, Pierre and Bath, Philip M and Wang, Xuan and Yan, Hongyi and Wang, Tingting and Yang, Yingying and Zhang, Yanli and Wang, Mengxing and Jing, Jing and Wang, Chunjuan and Wang, Yongjun and Wang, Yilong and Pan, Yuesong},
  title = {Dual Antiplatelet Therapy in Patients With Metabolic Syndrome After Mild Ischemic Stroke or Transient Ischemic Attack},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.041449}
}
Kostenlos starten →